329 related articles for article (PubMed ID: 25781993)
21. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
Zheng Y; Izumi K; Yao JL; Miyamoto H
Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
23. [Regulatory effect of Skp2 on the expression and transactivation of the androgen receptor in the progression of castration-resistant prostate cancer].
Song YT; Wu KJ; Wang XY; Na YG; Yin CM
Zhonghua Nan Ke Xue; 2016 Feb; 22(2):122-7. PubMed ID: 26939395
[TBL] [Abstract][Full Text] [Related]
24. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
25. Wild-type and specific mutant androgen receptor mediates transcription via 17β-estradiol in sex hormone-sensitive cancer cells.
Susa T; Ikaga R; Kajitani T; Iizuka M; Okinaga H; Tamamori-Adachi M; Okazaki T
J Cell Physiol; 2015 Jul; 230(7):1594-606. PubMed ID: 25536295
[TBL] [Abstract][Full Text] [Related]
26. Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors.
Pak S; Kim W; Kim Y; Song C; Ahn H
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2293-2301. PubMed ID: 31401673
[TBL] [Abstract][Full Text] [Related]
27. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
28. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
29. Androgen-Sensitized Apoptosis of HPr-1AR Human Prostate Epithelial Cells.
Chen C; Dienhart JA; Bolton EC
PLoS One; 2016; 11(5):e0156145. PubMed ID: 27203692
[TBL] [Abstract][Full Text] [Related]
30. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor.
Heisler LE; Evangelou A; Lew AM; Trachtenberg J; Elsholtz HP; Brown TJ
Mol Cell Endocrinol; 1997 Jan; 126(1):59-73. PubMed ID: 9027364
[TBL] [Abstract][Full Text] [Related]
31. Androgens stimulate erythropoiesis through the DNA-binding activity of the androgen receptor in non-hematopoietic cells.
McManus JF; Nguyen NN; Davey RA; MacLean HE; Pomilio G; McCormack MP; Chiu WS; Wei AH; Zajac JD; Curtis DJ
Eur J Haematol; 2020 Sep; 105(3):247-254. PubMed ID: 32311143
[TBL] [Abstract][Full Text] [Related]
32. Dihydrotestosterone increases the risk of bladder cancer in men.
Gil D; Zarzycka M; Dulińska-Litewka J; Ciołczyk-Wierzbicka D; Lekka M; Laidler P
Hum Cell; 2019 Jul; 32(3):379-389. PubMed ID: 31119584
[TBL] [Abstract][Full Text] [Related]
33. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
Chen F; Knecht K; Leu C; Rutledge SJ; Scafonas A; Gambone C; Vogel R; Zhang H; Kasparcova V; Bai C; Harada S; Schmidt A; Reszka A; Freedman L
J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):247-57. PubMed ID: 15336702
[TBL] [Abstract][Full Text] [Related]
34. Androgens modulate male-derived endothelial cell homeostasis using androgen receptor-dependent and receptor-independent mechanisms.
Torres-Estay V; Carreño DV; Fuenzalida P; Watts A; San Francisco IF; Montecinos VP; Sotomayor PC; Ebos J; Smith GJ; Godoy AS
Angiogenesis; 2017 Feb; 20(1):25-38. PubMed ID: 27679502
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors.
Plymate SR; Tennant MK; Culp SH; Woodke L; Marcelli M; Colman I; Nelson PS; Carroll JM; Roberts CT; Ware JL
Prostate; 2004 Nov; 61(3):276-90. PubMed ID: 15368471
[TBL] [Abstract][Full Text] [Related]
36. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells.
Need EF; Selth LA; Harris TJ; Birrell SN; Tilley WD; Buchanan G
Mol Endocrinol; 2012 Nov; 26(11):1941-52. PubMed ID: 23023562
[TBL] [Abstract][Full Text] [Related]
37. Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide.
Tong da Y; Wen XQ; Jin Y; Liu ZW; Sun HY; Zhou FJ; Wu XY
Asian Pac J Cancer Prev; 2010; 11(6):1805-9. PubMed ID: 21338237
[TBL] [Abstract][Full Text] [Related]
38. The Association of RGS2 and Slug in the Androgen-induced Acquisition of Mesenchymal Features of Breast MDA-MB-453 Cancer Cells.
Alsafadi DB; Abdullah MS; Bawadi R; Ahram M
Endocr Res; 2022; 47(2):64-79. PubMed ID: 35168462
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.
Bentel JM; Birrell SN; Pickering MA; Holds DJ; Horsfall DJ; Tilley WD
Mol Cell Endocrinol; 1999 Aug; 154(1-2):11-20. PubMed ID: 10509795
[TBL] [Abstract][Full Text] [Related]
40. Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells.
Nightingale J; Chaudhary KS; Abel PD; Stubbs AP; Romanska HM; Mitchell SE; Stamp GW; Lalani el-N
Neoplasia; 2003; 5(4):347-61. PubMed ID: 14511406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
